↓ Skip to main content

A web tool for designing and conducting phase I trials using the continual reassessment method

Overview of attention for article published in BMC Cancer, February 2018
Altmetric Badge

Mentioned by

twitter
1 X user

Citations

dimensions_citation
17 Dimensions

Readers on

mendeley
27 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
A web tool for designing and conducting phase I trials using the continual reassessment method
Published in
BMC Cancer, February 2018
DOI 10.1186/s12885-018-4038-x
Pubmed ID
Authors

Nolan A. Wages, Gina R. Petroni

Abstract

Broad implementation of model-based dose-finding methods, such as the continual reassessment method (CRM), has been limited, with traditional or modified 3 + 3 designs remaining in frequent use. Part of the reason is the lack of reliable, easy-to-use, and robust software tools for designing and implementing more efficient designs. With the aim of augmenting broader implementation of model-guided methods, we have developed a web application for the Bayesian CRM in the R programming language using the Shiny package. The application has two components, simulation and implementation. Within the application, one has the ability to generate simulated operating characteristics for the study design phase, and to sequentially provide the next dose recommendation for each new accrual or cohort based on the current data for the study implementation phase. At the conclusion of the study, it can be used to estimate the maximum tolerated dose (MTD). The web tool requires no programming knowledge, and it is free to access on any device with an internet browser. The application provides the type of simulation information that aid clinicians and reviewers in understanding operating characteristics for the accuracy and safety of the CRM, which we hope will augment phase I trial design. We believe that the development of this software will facilitate more efficient collaborations within study teams conducting single-agent dose-finding trials.

X Demographics

X Demographics

The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 27 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 27 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 6 22%
Other 5 19%
Student > Ph. D. Student 5 19%
Student > Bachelor 1 4%
Student > Doctoral Student 1 4%
Other 1 4%
Unknown 8 30%
Readers by discipline Count As %
Mathematics 5 19%
Medicine and Dentistry 4 15%
Pharmacology, Toxicology and Pharmaceutical Science 2 7%
Psychology 1 4%
Biochemistry, Genetics and Molecular Biology 1 4%
Other 2 7%
Unknown 12 44%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 22 August 2018.
All research outputs
#20,530,891
of 23,100,534 outputs
Outputs from BMC Cancer
#6,550
of 8,385 outputs
Outputs of similar age
#375,698
of 437,674 outputs
Outputs of similar age from BMC Cancer
#182
of 218 outputs
Altmetric has tracked 23,100,534 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 8,385 research outputs from this source. They receive a mean Attention Score of 4.3. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 437,674 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 218 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.